Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 15

Submit an article Journal homepage

764

Views

CrossRef citations to date

Altmetric

Review

Paclitaxel and docetaxel in the treatment of breast cancer

Emmanouel Saloustros University General Hospital of Heraklion, Department of Medical Oncology, PO Box 1352, 71110 Heraklion, Crete +30 2810 39278; +30 2810 392857; [email protected]

Dimitris Mavroudis University General Hospital of Heraklion, Department of Medical Oncology, PO Box 1352, 71110 Heraklion, Crete +30 2810 39278; +30 2810 392857; [email protected]

Vassilis Georgoulias University General Hospital of Heraklion, Department of Medical Oncology, PO Box 1352, 71110 Heraklion, Crete +30 2810 39278; +30 2810 392857; [email protected]

Pages 2603-2616 | Published online: 19 Sep 2008

Cite this article
https://doi.org/10.1517/14656566.9.15.2603

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Ahmedin J, Siegel R, Ward E. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96
PubMed Web of Science ®Google Scholar
Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology 2000;14:629-41
PubMed Web of Science ®Google Scholar
Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16
Web of Science ®Google Scholar
Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3:121-4
PubMed Web of Science ®Google Scholar
Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992;187:164-70
PubMed Web of Science ®Google Scholar
Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55
PubMed Web of Science ®Google Scholar
Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91
PubMed Web of Science ®Google Scholar
Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3 nm resolution. J Biol Chem 1994;269:31785-92
PubMed Web of Science ®Google Scholar
Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line [abstract 385]. Proc Am Assoc Cancer Res USA 1994;35:2292 (abstr. 385)
Google Scholar
Sawada N, Ishikava T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9
PubMed Web of Science ®Google Scholar
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33
PubMed Web of Science ®Google Scholar
Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-8
PubMed Web of Science ®Google Scholar
Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I. Preclinical experience. Anticancer Drugs 1995;6:339-55
PubMed Web of Science ®Google Scholar
Brooks TA, Minderman H, O'Loughlin KL, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003;11:1195-205
Google Scholar
Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
PubMed Web of Science ®Google Scholar
Ueda K, Cornwell M, Gottesman M, et al. The mdr1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141:956-62
PubMed Web of Science ®Google Scholar
Borst P, Evers R, Kool, M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302
PubMed Web of Science ®Google Scholar
Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6
PubMed Web of Science ®Google Scholar
Van Amerongen R, Berns A. TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev 2006;20:1975-81
PubMed Web of Science ®Google Scholar
Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81
PubMed Web of Science ®Google Scholar
Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;24:1797-805
Google Scholar
Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000;1:32-40
PubMedGoogle Scholar
Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-8
PubMed Web of Science ®Google Scholar
Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008;26:1642-9
PubMed Web of Science ®Google Scholar
Verrill MW, Lee J, Cameron DA, et al. Anglo-Ceptic IV: first results of a UK National Cancer Research Network randomized Phase III [harmacogenetic trial of weekly compared to 3-weekly paclitaxel in patients with locally advanced or metastatic breast cancer]. Proceedings ASCO Annual Meeting; 2007;25:LBA 1005
Google Scholar
Dieras V, Chevallier B, Kerbrat P, et al. A multicentre Phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996;4:650-6
Google Scholar
Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85
PubMed Web of Science ®Google Scholar
Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006;24:4963-7
PubMed Web of Science ®Google Scholar
Synold T, Newman E, Lenz HJ, et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD) [abstract]. Proc Am Soc Clin Oncol 1999;18:168a
Google Scholar
Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9
PubMed Web of Science ®Google Scholar
Loffler TM. Is there a place for ‘dose-dense’ weekly schedules of the taxoids? Semin Oncol 1998;12:32-4
Web of Science ®Google Scholar
Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12:1458-67
PubMed Web of Science ®Google Scholar
Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005;41:1117-26
PubMed Web of Science ®Google Scholar
Tsalic M, Gilboa M, Visel B, et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 2006;23:57-62
PubMed Web of Science ®Google Scholar
Ravdin PM. The international experience with docetaxel in the treatment of breast cancer. Oncology 1997;11:38-42
PubMedGoogle Scholar
Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30
PubMed Web of Science ®Google Scholar
Edgardo R, Jaime A, Mejia, et al. Phase III study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008;112:1455-61
PubMed Web of Science ®Google Scholar
Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the TAX 303 Study Group. J Clin Oncol 1999;17:2341-54
PubMed Web of Science ®Google Scholar
Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000;18:724-33
PubMed Web of Science ®Google Scholar
Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
PubMed Web of Science ®Google Scholar
Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355-64
PubMed Web of Science ®Google Scholar
Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-24
PubMed Web of Science ®Google Scholar
Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-201
PubMed Web of Science ®Google Scholar
Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-5
PubMed Web of Science ®Google Scholar
Sjostrom J, Collan J, Von Boguslawski K, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002;38:535-42
PubMed Web of Science ®Google Scholar
Icli E, Akbulut h, Uner A, et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a Phase III randomized study. Turkish Oncology Group. Ann Oncol 2002;13(Suppl 5):47
PubMed Web of Science ®Google Scholar
Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51
PubMed Web of Science ®Google Scholar
Vanhoefer U, Cao S, Harstrick A, et al. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 1997;8:1221-8
PubMed Web of Science ®Google Scholar
Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-8
PubMed Web of Science ®Google Scholar
Yonemori K, Katsumata N, Uno H. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat 2005;89:237-41
PubMed Web of Science ®Google Scholar
Bonneterre J, Dieras V, Tubiana Hulin M, et al. Epirubicin/docetaxel (ET) versus 5FU/epirubicin/cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer (MBC). Breast Cancer Res Treat 2001;69:215
Google Scholar
Mackey J, Paterson A, Dirix L, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients (pts) with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol USA 2002;21:25a
Google Scholar
Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75
PubMed Web of Science ®Google Scholar
Bontenbal M, Braun JJ, Creemers GJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081-8
PubMed Web of Science ®Google Scholar
Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002;20:114-21
Google Scholar
Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-15
PubMed Web of Science ®Google Scholar
Luck HJ, Thomssen C, Untch M, et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC): a study of the AGO Breast Cancer Group [abstract]. Proc Am Soc Clin Oncol USA 2000;19:73a
Google Scholar
Cassier P, Chabaud S, Trillet Lenoir V, et al. A phase III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008;109:343-50
PubMed Web of Science ®Google Scholar
Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter Phase II study. J Clin Oncol 2004;22:2321-7
PubMed Web of Science ®Google Scholar
Batista N, Perez Manga G, Constenla M, et al. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004;90:1740-6
PubMed Web of Science ®Google Scholar
Lueck H, Minckwitz GV, Du Bois A, et al. Epirubicin/paclitaxel (EP) vs capecitabine/paclitaxel (XP) in first-line metastatic breast cancer: a prospective, randomized multicentre phase III study of the AGO Breast Cancer Study Group [abstract]. J Clin Oncol 2006;24(18s):517
PubMedGoogle Scholar
Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients with anthracycline-pretreated metastatic breast cancer: sequential vs combined therapy results from a MOSG randomized phase III trial [abstract]. J Clin Oncol 2006;24:20s
Google Scholar
Blum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006;24:4384-90
PubMed Web of Science ®Google Scholar
Blum JL, Dees EC, Vukelja SJ. Phase II Trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 2007;7:465-70
PubMed Web of Science ®Google Scholar
O'Shaughnessy J, Miles D, Vukelja S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23
PubMed Web of Science ®Google Scholar
O'Shaughnessy J, Nag S, Calderillo Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline-pretreated metastatic breast cancer: interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol USA 2003;22:7a
PubMed Web of Science ®Google Scholar
Albain KS, Nag S, Calderillo Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel versus paclitaxel as frontline therapy for metastatic breast cancer: first report of overall survival [abstract]. Proc Am Soc Clin Oncol USA 2004;22:5a
Google Scholar
Chan S, Romieu G, Huober J, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European Phase III study [abstract]. J Clin Oncol 2005;23(16s):581
Web of Science ®Google Scholar
Zielinski C. Clinical considerations in the optimization of gemcitabine plus taxane as first-line treatment for metastatic breast cancer. Eur J Cancer Suppl 2007;5:17-22
Google Scholar
Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998;16:2087-94
PubMed Web of Science ®Google Scholar
Slamon DJ, Leyland Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
PubMed Web of Science ®Google Scholar
Seidman AD, Fornier MN, Esteva FJ. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95
PubMed Web of Science ®Google Scholar
Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004;90:36-40
PubMed Web of Science ®Google Scholar
Esteva FJ, Valero V, Booser D. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8
PubMed Web of Science ®Google Scholar
Montemurro F, Choa G, Faggiuolo R, et al. Safety and activity of docetaxel and trastuzumab in HER2-overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol 2003;26:95-7
PubMed Web of Science ®Google Scholar
Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071-7
PubMed Web of Science ®Google Scholar
Marty M, Cogqnetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
PubMed Web of Science ®Google Scholar
Robert N, Leyland Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92
PubMed Web of Science ®Google Scholar
Forbes JF, Pienkowski T, Valero V, et al. BRIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer [abstract]. J Clin Oncol 2006;24:932s
Google Scholar
Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast Cancer. N Engl J Med 2007;357:2666-76
PubMed Web of Science ®Google Scholar
Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract]. J Clin Oncol 2008;26(20s):LBA1011
Google Scholar
Estevez L, Muñoz M, Alvarezet I, et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer: a review of phase III trials. Cancer Treat Rev 2007;33:474-83
PubMed Web of Science ®Google Scholar
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results of NSABP B-28. J Clin Oncol 2005;21:3686-96
Google Scholar
Martin M, Rodriguez-Lescure A, Ruiz A, et al. Randomized phase III trial of fluorouracil. Epirubicin and cyclophosphamide alone or followed by paclitaxel for early breast cancer. JNCI 2008;100:805-14
PubMedGoogle Scholar
Martin M, Pienkowski T, MacKey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Eng J Med 2005;35:2302-13
Google Scholar
Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC Trial. J Clin Oncol 2006;24:5664-71
PubMed Web of Science ®Google Scholar
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83
PubMed Web of Science ®Google Scholar
Goldstein L, O'Neill A, Sparano J, et al. Concurrent doxorubicin plus docetaxel is not more effective than doxorubicin plus cyclophoshamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9
PubMed Web of Science ®Google Scholar
Jones SE, Savin MA, Holmes FA, et al. Phase III study comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7
PubMed Web of Science ®Google Scholar
Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older [abstract]. Breast Cancer Res Treat 2007;106(Suppl 1):S5
Google Scholar
Ficher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotraxate and fluorouacil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-96
PubMed Web of Science ®Google Scholar
Martin M, Villar A, Sole-Calco A, et al. Doxorubicin in combination with fluorouacil and cyclophosphamide (i.v. FAC regimen day 1, 21) versus methotraxate in combination with fluorouacil and cyclophosphamide (i.v. CMF regimen day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by GEICAM group. Ann Oncol 2003;14:833-42
PubMed Web of Science ®Google Scholar
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717
PubMed Web of Science ®Google Scholar
Hutching LF, Green SJ, Ravdin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate and fluorouacil versus cyclophosphamide, doxorubicin and fluorouacil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of intergroup protocol INT-0102. J Clin Oncol 2005;23:8313-21
PubMed Web of Science ®Google Scholar
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Eng J Med 2008;16:1663-71
Google Scholar
Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;11:2337-44
Google Scholar
Smith IC, Heys SD, Hutcheon AW. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66
PubMed Web of Science ®Google Scholar
Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five-year update of the Aberdeen trial [abstract 11]. San Antonio Breast Cancer Symposium 2003
Google Scholar
Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27
Google Scholar
Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine 2007;4:415-23
Google Scholar
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
PubMed Web of Science ®Google Scholar
Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proceedings ASCO Annual Meeting; 2007;25:1032
Google Scholar
Fornier M. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer 2007;10:757-63
Google Scholar
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;33:5210-7
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Paclitaxel and docetaxel in the treatment of breast cancer

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Paclitaxel and docetaxel in the treatment of breast cancer

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date